Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 294.62M | 277.25M | 232.28M | 722.68M | 439.44M | 46.55M |
Gross Profit | 242.37M | 227.80M | 182.12M | 460.53M | 265.87M | 32.64M |
EBITDA | -54.37M | 45.70M | 9.67M | 307.70M | 95.71M | -46.84M |
Net Income | -60.07M | 27.31M | -6.39M | 293.16M | 76.71M | -91.78M |
Balance Sheet | ||||||
Total Assets | 945.93M | 986.26M | 997.10M | 985.85M | 1.04B | 353.27M |
Cash, Cash Equivalents and Short-Term Investments | 661.34M | 713.83M | 742.30M | 624.39M | 545.95M | 165.04M |
Total Debt | 286.03M | 254.42M | 256.91M | 258.01M | 257.38M | 217.85M |
Total Liabilities | 414.99M | 389.46M | 375.02M | 404.84M | 816.87M | 294.58M |
Stockholders Equity | 530.94M | 596.80M | 622.07M | 581.01M | 222.37M | 58.69M |
Cash Flow | ||||||
Free Cash Flow | 54.02M | 60.16M | 96.46M | 55.58M | 326.05M | -103.32M |
Operating Cash Flow | 63.55M | 66.51M | 100.56M | 62.72M | 335.53M | -92.25M |
Investing Cash Flow | -13.96M | -18.04M | -153.93M | -316.00M | 14.22M | -26.53M |
Financing Cash Flow | -129.70M | -102.02M | 1.39M | 19.52M | 55.78M | 109.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.41B | ― | -5.19% | ― | 30.26% | -173.36% | |
72 Outperform | $1.76B | 29.06 | 6.32% | ― | 11.82% | ― | |
69 Neutral | $1.08B | 8.20 | 19.90% | ― | 8.05% | -8.46% | |
60 Neutral | $1.08B | ― | -12.27% | ― | 3.08% | -247.82% | |
52 Neutral | $1.24B | 64.45 | -10.45% | ― | 24.76% | -783.38% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
49 Neutral | $1.50B | ― | -20.41% | ― | 0.45% | -125.61% |
On April 14, 2025, Dynavax held its Annual Meeting where stockholders elected four Class I directors to serve until the 2028 meeting. The meeting also saw the approval of executive compensation, the ratification of Ernst & Young LLP as the independent auditor, and the amendment of the Certificate of Incorporation to declassify the Board. However, a stockholder proposal to amend the bylaws without stockholder approval was not passed.
The most recent analyst rating on (DVAX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.
On May 8, 2025, Dynavax Technologies Corporation announced the appointment of Joseph Metzinger as Vice President and Chief Accounting Officer, effective May 12, 2025. Metzinger, a seasoned financial executive with 19 years of experience, has been consulting for Dynavax since 2024 and previously held senior roles at CFGI and ACC Consumer Finance. His appointment includes a base salary, performance bonus, and stock options, with no familial or transactional ties to current executives.
The most recent analyst rating on (DVAX) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.